Skip to content
Menu

Vaxcyte, Inc. PCVX

Full chart Compare
Set alert

Price alert · PCVX

All alert types
55.39 USD -2.97 (-5.09%)

Regular-session close

55.39 0.00 0.00%

After hours · Nov 20, 4:26 PM ET

55.27 Day range 58.48
42.40 52-week range 90.75
YTD
+20.05%
1 year
+16.19%

5D -5.00 (-7.82%)

58606264FriMonTueWedThu58.90
Market cap
8.77B
EPS (ttm)
-8.05
Shares out
158.30M
Forward P/E
-8.06
YTD return
+20.05%
1-year return
+16.19%
50-day average
62.19
200-day average
57.78
Enterprise value
8.17B
Volume
1.91M
Avg volume
2.17M
Open
57.77
Previous close
58.36
Day's range
55.27 – 58.48
52-week range
42.40 – 90.75
Beta
1.29
Price target
116.40 (+110.1%)
Earnings date
Feb 23, 2027

Key statistics

Price / book
3.32
Free cash flow
-529.82M
Total cash
1.29B
Total debt
221.84M
Return on equity
-42.68%
Short % of float
9.81%

Fundamental scorecard

4 of 25 checks passed on PCVX’s reported financials

ValueGrowthProfitabilityHealthDividend

4of 25 checks passed

  • Value 1 of 5
  • Growth 0 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
PCVX Revenue — quarterly 0
PCVX Net income — quarterly -297.06M
PCVX EPS — quarterly -1.99

Earnings

PCVX recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 23, 2027Dec 30, 2026-1.93———
Nov 4, 2026Sep 30, 2026-2.11-1.99+0.12+5.69%
Aug 5, 2026Jun 30, 2026-2.06-1.97+0.09+4.37%
May 6, 2026Mar 31, 2026-1.78-2.30-0.52-29.40%
Feb 24, 2026Dec 31, 2025-1.53-1.80-0.27-17.67%
Nov 4, 2025Sep 30, 2025-1.27-1.56-0.29-22.83%

Upgrades / downgrades

PCVX analyst upgrades and downgrades
DateFirmActionFromTo
Oct 12, 2026Cantor FitzgeraldreitOverweightOverweight
Oct 5, 2026BTIGreitBuyBuy
Oct 5, 2026NeedhammainBuyBuy
Oct 5, 2026GuggenheimmainBuyBuy
Sep 28, 2026B of A SecuritiesmainBuyBuy
Sep 25, 2026NeedhamreitBuyBuy

About Vaxcyte, Inc.

Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
vaxcyte.com

News

Your note

Sign in to keep a note on PCVX — it syncs with the Stock Master app.

Insider holders

PCVX insider holders
InsiderRelationLatest transactionDateShares held
COWAN ELVIAOfficerSaleNov 1, 202627,860
DHALIWAL HARPREET S.OfficerSaleAug 4, 202676,756
EYDELMAN MIKHAILGeneral CounselSaleMar 4, 202541,620
GUGGENHIME ANDREWPresidentSaleAug 2, 2026167,026
JODAR LUISOfficerStock Award(Grant)Sep 3, 202652,632
LOXAM TERIDirectorStock Award(Grant)Jun 14, 202612,481

Institution ownership

PCVX institution ownership
Holder% heldSharesValueReported
FMR, LLC14.20%22,480,5921.25BSep 29, 2026
Janus Henderson Group Ltd.11.32%17,919,449992.56MSep 29, 2026
T. Rowe Price Investment Management, Inc.9.03%14,300,004792.08MSep 29, 2026
Blackrock Inc.7.69%12,179,969674.65MSep 29, 2026
RA Capital Management, L.P.7.25%11,474,599635.58MSep 29, 2026
Wellington Management Group, LLP4.89%7,733,961428.38MSep 29, 2026

Fund ownership

PCVX fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.90%4,587,918254.12MJun 29, 2026
T. ROWE PRICE CAPITAL APPRECIATION Fd., INC.-T. Rowe Price Capital App2.53%4,007,229221.96MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF2.15%3,411,349188.95MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund2.09%3,312,950183.50MJun 29, 2026
Fidelity Rutland Square TRT II-Strategic Advisers Fidelity U.S. Total 2.09%3,305,027183.07MSep 29, 2026
JANUS INVESTMENT FUND-Janus Henderson Forty Fund1.69%2,676,774148.27MSep 29, 2026